Abstract
Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes to the liver, which drives patient mortality. CA19-9 is elevated in most PDAC tumors and is widely used as a clinical biomarker. Elevated serum levels are associated with poor outcomes. However, whether CA19-9 functionally contributes to metastatic progression has not been fully defined, in part because mice lack endogenous CA19-9 expression. Here, using syngeneic murine PDAC cells engineered to express CA19-9, we investigated its functional role in liver metastasis. In splenic injection models, CA19-9 expression markedly increased liver metastatic burden by promoting both metastatic seeding and subsequent metastatic outgrowth. In vitro , CA19-9 enhanced tumor cell adhesion to endothelial cells through interaction with E-selectin. Metastatic seeding of CA19-9-expressing cells was reduced by genetic deletion of E-selectin or antibody neutralization of either CA19-9 or E-selectin in vivo . Therapeutic targeting of CA19-9 with a neutralizing antibody markedly reduced liver metastatic burden after metastatic seeding. CA19-9 expression increased AKT signaling in PDAC cells and liver metastases, and CA19-9 levels correlated with AKT activation in human PDAC tissues. These findings show that CA19-9 promotes PDAC liver metastasis through E-selectin-dependent metastatic seeding and AKT-associated metastatic outgrowth, highlighting CA19-9 as a functional mediator of PDAC metastasis and a potential therapeutic target.
Funding Information
  • Pioneer Fund Postdoctoral Scholar Award
  • Salk Institute Cancer Training Grant (T32CA009370)
  • Mission Cure Capital LLC
  • Conrad Prebys Foundation
  • Paul M. Angell Family Foundation
  • Pancreatic Cancer Action Network (19-20-ENGL)
  • Curebound (20DG11)
  • Helen McLoraine Developmental Chair
  • National Cancer Institute (P01 CA265762)
  • Emerald Foundation
  • NIH-NCI CCSG (P30 CA014195)
  • NIH-NIA San Diego Nathan Shock Center (P30 AG068635)
  • Leona M. and Harry B. Helmsley Charitable Trust
  • National Cancer Institute Cancer Center Support Grant (P30 CA231100)

This publication has 40 references indexed in Scilit: